CGRP
News/ News/ Sales and Marketing
Pfizer upgrades Biohaven alliance to a takeover bid
Phil Taylor
Biohaven Pharmaceuticals, CGRP, M&A, migraine, Pfizer
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Pfizer/Biohaven migraine drug rimegepant gets EU green light
Phil Taylor
AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, Pfizer, Qulipta, Vydura
0 Comment
Amid crowded migraine market, Lundbeck goes its own way
Phil Taylor
CGRP, Lundbeck, migraine, PACAP, Vyepti
0 Comment
News/ News/ Sales and Marketing
Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug
Phil Taylor
Biohaven Pharmaceuticals, central nervous system, CGRP, migraine, partnering, Pfizer
0 Comment
AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash
Phil Taylor
AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, prevention, Qulipta
0 Comment
News/ News/ R&D/ Top stories
Novartis’ Aimovig tops topiramate in migraine face-off
Phil Taylor
Aimovig, Amgen, CGRP, migraine, neurology, Novartis, prevention
0 Comment
CHMP turns down Lilly’s Emgality for cluster headache
Phil Taylor
CGRP, chronic migraine, cluster headache, Eli Lilly, Emgality
0 Comment